Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
33 patients with advanced gastric cancer who received neoadjuvant cadonilimab combined with FLOT therapy and subsequently underwent surgery.
I · Intervention 중재 / 시술
neoadjuvant cadonilimab combined with FLOT therapy and subsequently underwent surgery
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Variations in SLM across different anatomical sites have distinct effects on treatment outcomes, the trunk has the most significant impact, followed by the lower limbs and the upper limbs have the least effect. [TRIAL REGISTRATION] www.chictr.org.cn, identifier ChiCTR2200066893.
[OBJECTIVE] This study aimed.
- p-value P < 0.05
APA
Liu P, Li N, et al. (2025). Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes.. Frontiers in oncology, 15, 1601819. https://doi.org/10.3389/fonc.2025.1601819
MLA
Liu P, et al.. "Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes.." Frontiers in oncology, vol. 15, 2025, pp. 1601819.
PMID
40904512 ↗
Abstract 한글 요약
[OBJECTIVE] This study aimed. to explore the predictive value of body composition changes in the efficacy of neoadjuvant cadonilimab combined with FLOT therapy for advanced gastric cancer and provide a reference for personalized treatment.
[METHODS] A retrospective study was conducted on 33 patients with advanced gastric cancer who received neoadjuvant cadonilimab combined with FLOT therapy and subsequently underwent surgery. Body composition data were obtained using the InBody 720 body composition analysis device. Based on treatment response, patients were classified into the objective response group and the no-progression group. Quantitative data were presented as median and interquartile range. The Mann-Whitney U test was used for intergroup comparisons, analyzing the relationship between body composition changes before and after neoadjuvant therapy and treatment outcomes.
[RESULTS] The changes in LBM, SLM, SMM, VFA, LEFT ARM SLM, RIGHT ARM SLM, LEFT LEG SLM, RIGHT LEG SLM, TRUNK SLM and IMPEDANCE before and after neoadjuvant therapy showed significant differences (P < 0.05) between two groups, indicating statistical significance. LBM, SLM and SMM showed a decreasing trend in both groups and the reduction was greater in the no-progression group than in the objective response group; VFA expressed a significant reduction in the objective response group, but it tended to increase in the no-progression group; IMPEDANCE showed a significant increase in the objective response group, but the change was insignificant in the no-progression group. SLM in the trunk and limbs showed a decreasing trend in both groups and the reduction was greater in the no-progression group than in the objective response group. The changes in HEIGHT, WEIGHT, BFM, PBF, LEFT ARM MBF, RIGHT ARM MBF, LEFT LEG MBF, RIGHT LEG MBF, TRUNK MBF, WHR and WAIST showed no significant differences (P ≥ 0.05) between two groups, indicating they were not statistically significant.
[CONCLUSIONS] The changes in LBM, SLM, SMM, VFA and IMPEDANCE can predict the efficacy of neoadjuvant cadonilimab plus FLOT therapy in advanced gastric cancer, especially LBM, SLM and SMM show the highest predictive value. Variations in SLM across different anatomical sites have distinct effects on treatment outcomes, the trunk has the most significant impact, followed by the lower limbs and the upper limbs have the least effect.
[TRIAL REGISTRATION] www.chictr.org.cn, identifier ChiCTR2200066893.
[METHODS] A retrospective study was conducted on 33 patients with advanced gastric cancer who received neoadjuvant cadonilimab combined with FLOT therapy and subsequently underwent surgery. Body composition data were obtained using the InBody 720 body composition analysis device. Based on treatment response, patients were classified into the objective response group and the no-progression group. Quantitative data were presented as median and interquartile range. The Mann-Whitney U test was used for intergroup comparisons, analyzing the relationship between body composition changes before and after neoadjuvant therapy and treatment outcomes.
[RESULTS] The changes in LBM, SLM, SMM, VFA, LEFT ARM SLM, RIGHT ARM SLM, LEFT LEG SLM, RIGHT LEG SLM, TRUNK SLM and IMPEDANCE before and after neoadjuvant therapy showed significant differences (P < 0.05) between two groups, indicating statistical significance. LBM, SLM and SMM showed a decreasing trend in both groups and the reduction was greater in the no-progression group than in the objective response group; VFA expressed a significant reduction in the objective response group, but it tended to increase in the no-progression group; IMPEDANCE showed a significant increase in the objective response group, but the change was insignificant in the no-progression group. SLM in the trunk and limbs showed a decreasing trend in both groups and the reduction was greater in the no-progression group than in the objective response group. The changes in HEIGHT, WEIGHT, BFM, PBF, LEFT ARM MBF, RIGHT ARM MBF, LEFT LEG MBF, RIGHT LEG MBF, TRUNK MBF, WHR and WAIST showed no significant differences (P ≥ 0.05) between two groups, indicating they were not statistically significant.
[CONCLUSIONS] The changes in LBM, SLM, SMM, VFA and IMPEDANCE can predict the efficacy of neoadjuvant cadonilimab plus FLOT therapy in advanced gastric cancer, especially LBM, SLM and SMM show the highest predictive value. Variations in SLM across different anatomical sites have distinct effects on treatment outcomes, the trunk has the most significant impact, followed by the lower limbs and the upper limbs have the least effect.
[TRIAL REGISTRATION] www.chictr.org.cn, identifier ChiCTR2200066893.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Exosomes for Polycystic Ovary Syndrome Treatment: Mechanisms and Therapeutic Potential.
- Retraction: ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer.
- Pathologic response and safety of preoperative treatment regimens in gastric cancer undergoing D2 gastrectomy: a real-world cohort study.
- ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer.
- ZNF711 promotes enzalutamide resistance through transcriptional and epigenetic modification of the androgen receptor signaling pathway.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.
- Association Between Vitamin D Deficiency, Malnutrition, and Systemic Inflammation in Advanced Colorectal Cancer: A Hospital-Based Cross-Sectional Study.
- Association of body composition and nutritional status with survival in stage IV colorectal cancer patients who underwent resection: a retrospective cohort study.
- Perioperative chemotherapy (FLOT 4 + 4) versus total neoadjuvant therapy (TNT; FLOT ×8) for resectable gastric cancer: A systematic review and exploratory meta-analysis.
- Malnutrition, Skeletal Muscle Loss and Mucosal Toxicity in Head and Neck Cancer: Nutritional Targets Beyond Energy Replacement.
- Prognostic Impact and Postoperative Management Following Poor Pathological Response to Perioperative FLOT in Resectable Gastric and GEJ Adenocarcinoma: A Systematic Review and Meta-Analysis.